HIV-1 Envelope Glycosylation and the Signal Peptide
Open Access
- 19 February 2021
- Vol. 9 (2), 176
- https://doi.org/10.3390/vaccines9020176
Abstract
The RV144 trial represents the only vaccine trial to demonstrate any protective effect against HIV-1 infection. While the reason(s) for this protection are still being evaluated, it serves as justification for widespread efforts aimed at developing new, more effective HIV-1 vaccines. Advances in our knowledge of HIV-1 immunogens and host antibody responses to these immunogens are crucial to informing vaccine design. While the envelope (Env) protein is the only viral protein present on the surface of virions, it exists in a complex trimeric conformation and is decorated with an array of variable N-linked glycans, making it an important but difficult target for vaccine design. Thus far, efforts to elicit a protective humoral immune response using structural mimics of native Env trimers have been unsuccessful. Notably, the aforementioned N-linked glycans serve as a component of many of the epitopes crucial for the induction of potentially protective broadly neutralizing antibodies (bnAbs). Thus, a greater understanding of Env structural determinants, most critically Env glycosylation, will no doubt be of importance in generating effective immunogens. Recent studies have identified the HIV-1 Env signal peptide (SP) as an important contributor to Env glycosylation. Further investigation into the mechanisms by which the SP directs glycosylation will be important, both in the context of understanding HIV-1 biology and in order to inform HIV-1 vaccine design.Funding Information
- National Institutes of Health (AI140909)
This publication has 178 references indexed in Scilit:
- Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort StudiesPLoS Medicine, 2013
- Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escapeNature Medicine, 2012
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialThe New England Journal of Medicine, 2012
- Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysNature, 2012
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Nature, 2011
- HIV-1 Envelope Glycoprotein Biosynthesis, Trafficking, and IncorporationJournal of Molecular Biology, 2011
- Expression-System-Dependent Modulation of HIV-1 Envelope Glycoprotein Antigenicity and ImmunogenicityJournal of Molecular Biology, 2010
- Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designNature Reviews Immunology, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandThe New England Journal of Medicine, 2009
- Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B virusesVirology, 2008